- Home
- PPBT vs BNOX Comparison
PPBT vs BNOX Comparison
Compare PPBT & BNOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- BNOX
- Stock Information
- Founded
- PPBT 2010
- BNOX 1996
- Country
- PPBT Israel
- BNOX Australia
- Employees
- PPBT N/A
- BNOX N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- BNOX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PPBT Health Care
- BNOX Health Care
- Exchange
- PPBT Nasdaq
- BNOX Nasdaq
- Market Cap
- PPBT 6.7M
- BNOX 6.3M
- IPO Year
- PPBT N/A
- BNOX 2021
- Fundamental
- Price
- PPBT $3.61
- BNOX $0.26
- Analyst Decision
- PPBT Strong Buy
- BNOX Strong Buy
- Analyst Count
- PPBT 2
- BNOX 1
- Target Price
- PPBT $126.50
- BNOX $8.00
- AVG Volume (30 Days)
- PPBT 2.7M
- BNOX 651.2K
- Earning Date
- PPBT 11-15-2024
- BNOX 01-01-0001
- Dividend Yield
- PPBT N/A
- BNOX N/A
- EPS Growth
- PPBT N/A
- BNOX N/A
- EPS
- PPBT N/A
- BNOX N/A
- Revenue
- PPBT N/A
- BNOX N/A
- Revenue This Year
- PPBT N/A
- BNOX N/A
- Revenue Next Year
- PPBT N/A
- BNOX N/A
- P/E Ratio
- PPBT N/A
- BNOX N/A
- Revenue Growth
- PPBT N/A
- BNOX N/A
- 52 Week Low
- PPBT $2.00
- BNOX $0.18
- 52 Week High
- PPBT $20.60
- BNOX $1.60
- Technical
- Relative Strength Index (RSI)
- PPBT 47.73
- BNOX 47.76
- Support Level
- PPBT $3.56
- BNOX $0.27
- Resistance Level
- PPBT $4.22
- BNOX $0.35
- Average True Range (ATR)
- PPBT 1.42
- BNOX 0.03
- MACD
- PPBT -0.07
- BNOX 0.00
- Stochastic Oscillator
- PPBT 3.36
- BNOX 18.78
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.
About BNOX Bionomics Limited American Depository Shares
Bionomics Ltd is a clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.